25/07/201826/01/2024 Helix BioPharma Corp. Completes Fourth Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47 admin 0 Comments
12/06/201826/01/2024 Helix BioPharma Corp. Announces Fiscal Third Quarter 2018 Results admin 0 Comments
30/05/201826/01/2024 Helix BioPharma Corp. Completes Third Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47 admin 0 Comments
10/04/201826/01/2024 Helix BioPharma Corp. Announces Regulatory Approval to Dose Patients in a Phase II Randomized Study of L-DOS47 with Vinorelbine and Cisplatin admin 0 Comments
22/03/201826/01/2024 Helix BioPharma Corp Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to its Scientific and Strategic Advisory Board admin 0 Comments
21/03/201826/01/2024 Helix BioPharma Corp Signs Collaboration Agreement with Promab biotechnologies to Co-develop CAR-T for Hematological Malignacies admin 0 Comments
19/03/201826/01/2024 Helix BioPharma Corp. Announces Fiscal Second Quarter 2018 Results admin 0 Comments